$1.5b
Jazz Pharmaceuticals targets leukemia. The Dublin company is buying New Jersey’s Celator, maker of Vyxeos, an experimental medicine for a rare blood cancer.
Jazz Pharmaceuticals targets leukemia. The Dublin company is buying New Jersey’s Celator, maker of Vyxeos, an experimental medicine for a rare blood cancer.